A method of treating exudative AMD is administering to the vitreous drugs that inhibit formation of pathological blood vessels. Such therapy primarily aims at inhibiting disease progress.
The treatment usually involves several injections, which are applied from time to time. A number of injections and time intervals between subsequent injections is determined by the ophthalmologist, based on the results of fluorescein angiography, OCT and other diagnostic examinations.
Intravitreal injections of anti-VEGF agents (Elyea, Lucentis) are used in case of retinal diseases, particularly in an exudate type of Age-related Macular Degeneration (AMD), diabetic retinopathy, high myopia, and retinal vein occlusion.
VEGF is a growth factor of abnormal blood vessels. In eyes which suffer from macular degeneration, its level is too high. Anti-VEGF agents block the VEGF factor permanently.
The intraocular injection is performed in the Eye Institute as a “walk-in, walk-out” outpatient procedure, in the treatment room. The procedure is performed by an ophthalmologist – a highly experienced specialist assisted by a nurse.